Key Points Roche's leading weight loss and diabetes candidate has posted excellent Phase 2 clinical trial results. The medicine could carve out a solid niche in this field. Roche may still not be able to take the lead from Eli Lilly, but there are other reasons to invest in the company. 10 stocks we like better than Roche Holding AG › Novo Nordisk (NYSE:NVO) has been a pioneer in the market for weight loss drugs, but Eli Lilly (NYSE:LLY) has since emerged as the leader. Both drugmakers have deep pipelines that could allow them to remain ahead of their competitors in the coming years as the anti-obesity area continues to expand rapidly. But could another pharmaceutical giant eventually take the lead?
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.